Utah Medical Products Inc
UTMD- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0000706698
In the last 90 days, Utah Medical Products Inc insiders filed 1 open-market purchase and 0 sales; 116 institutions reported holding it in 13F filings for Q2 2026, worth $159.9M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 11:25 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K/A | 10-K |
| Reported | Jan 29, 2026 | Jan 28, 2025 | Jan 30, 2024 | Jan 31, 2023 | Feb 2, 2022 |
| Revenue | $38.5M | $40.9M | $50.2M | $52.3M | $49.1M |
| Cost of revenue | $16.5M | $16.8M | $20.2M | $20.1M | $18.1M |
| Gross profit | $22.0M | $24.1M | $30.0M | $32.2M | $30.9M |
| Research and development | $668.0K | $813.0K | $560.0K | $493.0K | $526.0K |
| Selling, general and administrative | $7.88M | $7.83M | $11.0M | $10.4M | $10.1M |
| Operating income | $11.4M | $13.6M | $16.8M | $19.8M | $18.9M |
| Income tax | $2.82M | $2.93M | $3.45M | $4.19M | $4.27M |
| Net income | $11.3M | $13.9M | $16.6M | $16.5M | $14.8M |
| EPS, basic | $3.48 | $3.96 | $4.58 | $4.53 | $4.05 |
| EPS, diluted | $3.48 | $3.96 | $4.57 | $4.52 | $4.04 |
| Weighted shares, basic | 3.24M | 3.50M | 3.63M | 3.64M | 3.65M |
| Weighted shares, diluted | 3.24M | 3.50M | 3.64M | 3.64M | 3.66M |
| Margins and growth | |||||
| Gross margin | 57.1% | 59.0% | 59.8% | 61.6% | 63.0% |
| Operating margin | 29.6% | 33.2% | 33.4% | 37.9% | 38.5% |
| Net margin | 29.3% | 33.9% | 33.1% | 31.5% | 30.1% |
| Revenue growth, year over year | −5.8% | −18.6% | −3.9% | +6.6% | +16.3% |
| Net income growth, year over year | −18.7% | −16.6% | +1.0% | +11.4% | +37.0% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K/A | 10-K |
| Reported | Jan 29, 2026 | Jan 28, 2025 | Jan 30, 2024 | Jan 31, 2023 | Feb 2, 2022 |
| Cash and equivalents | $85.8M | $83.0M | $92.9M | $75.1M | $61.0M |
| Accounts receivable | $3.52M | $4.09M | $3.39M | $5.54M | $5.13M |
| Inventory | $7.93M | $8.81M | $9.58M | $8.81M | $6.60M |
| Total current assets | $97.7M | $96.3M | $106.3M | $89.9M | $73.2M |
| Property, plant and equipment | $9.91M | $9.76M | $10.6M | $10.2M | $11.1M |
| Goodwill | $14.1M | $13.6M | $13.7M | $13.4M | $14.1M |
| Intangible assets | $840.0K | $2.87M | $4.95M | $10.4M | $17.3M |
| Total assets | $122.5M | $122.5M | $135.5M | $123.9M | $115.6M |
| Accounts payable | $911.0K | $696.0K | $769.0K | $1.22M | $761.0K |
| Total current liabilities | $2.60M | $3.76M | $4.71M | $5.96M | $3.75M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 |
| Total liabilities | $3.27M | $5.11M | $7.14M | $9.62M | $8.50M |
| Shareholders' equity | $119.3M | $117.4M | $128.3M | $114.3M | $107.1M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K/A | 10-K |
| Reported | Jan 29, 2026 | Jan 28, 2025 | Jan 30, 2024 | Jan 31, 2023 | Feb 2, 2022 |
| Operating cash flow | $14.7M | $14.8M | $22.3M | $21.1M | $21.2M |
| Capital expenditures | $371.0K | $230.0K | $639.0K | $809.0K | $552.0K |
| Free cash flow | $14.3M | $14.6M | $21.6M | $20.3M | $20.7M |
| Stock-based compensation | $373.0K | $256.0K | $225.0K | $183.0K | $166.0K |
| Dividends paid | $3.98M | $4.26M | $4.28M | $3.16M | $11.5M |
| Share buybacks | $8.36M | $20.0M | $0 | $2.50M | $0 |
| Investing cash flow | -$371.0K | -$208.0K | -$639.0K | -$818.0K | -$552.0K |
| Financing cash flow | -$12.3M | -$23.8M | -$4.17M | -$5.48M | -$10.9M |
| Net change in cash | $2.78M | -$9.89M | $17.8M | $14.1M | $9.38M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 1.0% | 0.6% | 0.4% | 0.4% | 0.3% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Aug 11, 2026 | 3.18M | −0.7% | SEC |
| May 11, 2026 | 3.18M | −2.0% | SEC |
| Mar 26, 2026 | 3.19M | −2.9% | SEC |
| Nov 10, 2025 | 3.20M | −5.5% | SEC |
| Aug 11, 2025 | 3.21M | −7.8% | SEC |
| May 12, 2025 | 3.25M | −7.9% | SEC |
| Mar 25, 2025 | 3.28M | −8.6% | SEC |
| Nov 11, 2024 | 3.39M | −6.6% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.